Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial
Background: Allergen immunotherapy is the only treatment that may modify the natural course of allergic diseases. Sublingual immunotherapy (SLIT) is a promising treatment, especially for children. Few studies currently exist related to optimal dosing for Blomia tropicalis. Methods: This was a double...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455124001522 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582160847994880 |
|---|---|
| author | Priscilla Rios Cordeiro Macedo, MD, MSc Priscila Moraes, MD Luísa Karla Arruda, MD, PhD Fábio Fernandes Morato Castro, MD, PhD Jorge Kalil, MD, PhD Clóvis Eduardo Santos Galvão, MD, PhD |
| author_facet | Priscilla Rios Cordeiro Macedo, MD, MSc Priscila Moraes, MD Luísa Karla Arruda, MD, PhD Fábio Fernandes Morato Castro, MD, PhD Jorge Kalil, MD, PhD Clóvis Eduardo Santos Galvão, MD, PhD |
| author_sort | Priscilla Rios Cordeiro Macedo, MD, MSc |
| collection | DOAJ |
| description | Background: Allergen immunotherapy is the only treatment that may modify the natural course of allergic diseases. Sublingual immunotherapy (SLIT) is a promising treatment, especially for children. Few studies currently exist related to optimal dosing for Blomia tropicalis. Methods: This was a double-blind, randomized, placebo-controlled trial of SLIT to treat house dust mite-induced Allergic Rhinitis (AR). A total of 65 patients, ages 12–16 years, were treated for 12 months and randomized into SLIT versus placebo. The SLIT group received a combination of Dermatophagoides pteronyssinus and Blomia tropicalis allergens. Sensitization was confirmed by skin prick test or serum specific IgE. Total Nasal Symptom Score (TNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), current treatment, and need for medication to control symptoms were ascertained during the study. Total serum IgE, serum specific IgE, and IgG4 levels for Der p 1 and Blo t were assessed at baseline and, 6 and 12 months after treatment. Results: There was no significant difference in the number of adverse events between groups. The SLIT group showed a significant reduction in antihistamine use to control symptoms (p < 0.0001) compared to placebo. There was no significant change in serum total IgE, serum specific IgE, and IgG4 for either allergen when comparing the SLIT and placebo groups. Conclusion: After 1 year, SLIT using a dose of 1 mcg of Der p 1/day and 753 UBE of Blo t/day lowered the need for medications for break-through symptoms, with a good safety profile.'' |
| format | Article |
| id | doaj-art-53be6d8a9b6b49b1ba7b3df4765780e2 |
| institution | Kabale University |
| issn | 1939-4551 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj-art-53be6d8a9b6b49b1ba7b3df4765780e22025-01-30T05:13:53ZengElsevierWorld Allergy Organization Journal1939-45512025-02-01182101020Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trialPriscilla Rios Cordeiro Macedo, MD, MSc0Priscila Moraes, MD1Luísa Karla Arruda, MD, PhD2Fábio Fernandes Morato Castro, MD, PhD3Jorge Kalil, MD, PhD4Clóvis Eduardo Santos Galvão, MD, PhD5Clinical Immunology and Allergy Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, BrazilClinical Immunology and Allergy Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, BrazilDepartments of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, BrazilClinical Immunology and Allergy Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, BrazilClinical Immunology and Allergy Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, BrazilClinical Immunology and Allergy Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, Brazil; Corresponding author. Avenida Dr Enéas de Carvalho Aguiar, 155 8º andar Bloco 3 – Cerqueira César, 05403-000, São Paulo, SP, Brazil.Background: Allergen immunotherapy is the only treatment that may modify the natural course of allergic diseases. Sublingual immunotherapy (SLIT) is a promising treatment, especially for children. Few studies currently exist related to optimal dosing for Blomia tropicalis. Methods: This was a double-blind, randomized, placebo-controlled trial of SLIT to treat house dust mite-induced Allergic Rhinitis (AR). A total of 65 patients, ages 12–16 years, were treated for 12 months and randomized into SLIT versus placebo. The SLIT group received a combination of Dermatophagoides pteronyssinus and Blomia tropicalis allergens. Sensitization was confirmed by skin prick test or serum specific IgE. Total Nasal Symptom Score (TNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), current treatment, and need for medication to control symptoms were ascertained during the study. Total serum IgE, serum specific IgE, and IgG4 levels for Der p 1 and Blo t were assessed at baseline and, 6 and 12 months after treatment. Results: There was no significant difference in the number of adverse events between groups. The SLIT group showed a significant reduction in antihistamine use to control symptoms (p < 0.0001) compared to placebo. There was no significant change in serum total IgE, serum specific IgE, and IgG4 for either allergen when comparing the SLIT and placebo groups. Conclusion: After 1 year, SLIT using a dose of 1 mcg of Der p 1/day and 753 UBE of Blo t/day lowered the need for medications for break-through symptoms, with a good safety profile.''http://www.sciencedirect.com/science/article/pii/S1939455124001522Allergen immunotherapyAllergic rhinitisBlomia tropicalisDermatophagoides pteronyssinusSublingual immunotherapyDrops |
| spellingShingle | Priscilla Rios Cordeiro Macedo, MD, MSc Priscila Moraes, MD Luísa Karla Arruda, MD, PhD Fábio Fernandes Morato Castro, MD, PhD Jorge Kalil, MD, PhD Clóvis Eduardo Santos Galvão, MD, PhD Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial World Allergy Organization Journal Allergen immunotherapy Allergic rhinitis Blomia tropicalis Dermatophagoides pteronyssinus Sublingual immunotherapy Drops |
| title | Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial |
| title_full | Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial |
| title_fullStr | Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial |
| title_full_unstemmed | Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial |
| title_short | Efficacy and safety of sublingual immunotherapy using a combination of Dermatophagoides pteronyssinus and Blomia tropicalis extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial |
| title_sort | efficacy and safety of sublingual immunotherapy using a combination of dermatophagoides pteronyssinus and blomia tropicalis extracts in patients with allergic rhinitis a randomized double blind placebo controlled trial |
| topic | Allergen immunotherapy Allergic rhinitis Blomia tropicalis Dermatophagoides pteronyssinus Sublingual immunotherapy Drops |
| url | http://www.sciencedirect.com/science/article/pii/S1939455124001522 |
| work_keys_str_mv | AT priscillarioscordeiromacedomdmsc efficacyandsafetyofsublingualimmunotherapyusingacombinationofdermatophagoidespteronyssinusandblomiatropicalisextractsinpatientswithallergicrhinitisarandomizeddoubleblindplacebocontrolledtrial AT priscilamoraesmd efficacyandsafetyofsublingualimmunotherapyusingacombinationofdermatophagoidespteronyssinusandblomiatropicalisextractsinpatientswithallergicrhinitisarandomizeddoubleblindplacebocontrolledtrial AT luisakarlaarrudamdphd efficacyandsafetyofsublingualimmunotherapyusingacombinationofdermatophagoidespteronyssinusandblomiatropicalisextractsinpatientswithallergicrhinitisarandomizeddoubleblindplacebocontrolledtrial AT fabiofernandesmoratocastromdphd efficacyandsafetyofsublingualimmunotherapyusingacombinationofdermatophagoidespteronyssinusandblomiatropicalisextractsinpatientswithallergicrhinitisarandomizeddoubleblindplacebocontrolledtrial AT jorgekalilmdphd efficacyandsafetyofsublingualimmunotherapyusingacombinationofdermatophagoidespteronyssinusandblomiatropicalisextractsinpatientswithallergicrhinitisarandomizeddoubleblindplacebocontrolledtrial AT cloviseduardosantosgalvaomdphd efficacyandsafetyofsublingualimmunotherapyusingacombinationofdermatophagoidespteronyssinusandblomiatropicalisextractsinpatientswithallergicrhinitisarandomizeddoubleblindplacebocontrolledtrial |